Advent Pharma Ltd. (DSE:ADVENT)

Advent Pharma Statistics

Total Valuation

Advent Pharma has a market cap or net worth of BDT 1.27 billion. The enterprise value is 1.34 billion.

Market Cap	1.27B
Enterprise Value	1.34B

Important Dates

The last earnings date was Sunday, October 26, 2025.

Earnings Date	Oct 26, 2025
Ex-Dividend Date	Nov 23, 2025

Share Statistics

Advent Pharma has 93.13 million shares outstanding.

Current Share Class	93.13M
Shares Outstanding	93.13M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

The trailing PE ratio is 18.94.

PE Ratio	18.94
Forward PE	n/a
PS Ratio	2.53
PB Ratio	0.83
P/TBV Ratio	0.83
P/FCF Ratio	61.59
P/OCF Ratio	11.04
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.45, with an EV/FCF ratio of 65.19.

EV / Earnings	20.05
EV / Sales	2.68
EV / EBITDA	8.45
EV / EBIT	14.03
EV / FCF	65.19

Financial Position

The company has a current ratio of 1.51, with a Debt / Equity ratio of 0.05.

Current Ratio	1.51
Quick Ratio	1.01
Debt / Equity	0.05
Debt / EBITDA	0.48
Debt / FCF	3.69
Interest Coverage	10.44

Financial Efficiency

Return on equity (ROE) is 4.46% and return on invested capital (ROIC) is 3.79%.

Return on Equity (ROE)	4.46%
Return on Assets (ROA)	3.15%
Return on Invested Capital (ROIC)	3.79%
Return on Capital Employed (ROCE)	5.48%
Revenue Per Employee	1.58M
Profits Per Employee	210,956
Employee Count	317
Asset Turnover	0.26
Inventory Turnover	4.87

Taxes

In the past 12 months, Advent Pharma has paid 19.41 million in taxes.

Income Tax	19.41M
Effective Tax Rate	22.50%

Stock Price Statistics

The stock price has decreased by -23.60% in the last 52 weeks. The beta is 0.36, so Advent Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.36
52-Week Price Change	-23.60%
50-Day Moving Average	14.33
200-Day Moving Average	14.89
Relative Strength Index (RSI)	47.55
Average Volume (20 Days)	161,312

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Advent Pharma had revenue of BDT 500.49 million and earned 66.87 million in profits. Earnings per share was 0.72.

Revenue	500.49M
Gross Profit	175.63M
Operating Income	95.58M
Pretax Income	86.29M
Net Income	66.87M
EBITDA	158.05M
EBIT	95.58M
Earnings Per Share (EPS)	0.72

Balance Sheet

The company has 1.77 million in cash and 75.79 million in debt, giving a net cash position of -74.03 million or -0.79 per share.

Cash & Cash Equivalents	1.77M
Total Debt	75.79M
Net Cash	-74.03M
Net Cash Per Share	-0.79
Equity (Book Value)	1.53B
Book Value Per Share	16.43
Working Capital	95.75M

Cash Flow

In the last 12 months, operating cash flow was 114.74 million and capital expenditures -94.18 million, giving a free cash flow of 20.56 million.

Operating Cash Flow	114.74M
Capital Expenditures	-94.18M
Free Cash Flow	20.56M
FCF Per Share	0.22

Margins

Gross margin is 35.09%, with operating and profit margins of 19.10% and 13.36%.

Gross Margin	35.09%
Operating Margin	19.10%
Pretax Margin	17.24%
Profit Margin	13.36%
EBITDA Margin	31.58%
EBIT Margin	19.10%
FCF Margin	4.11%

Dividends & Yields

This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 0.37%.

Dividend Per Share	0.05
Dividend Yield	0.37%
Dividend Growth (YoY)	-50.00%
Years of Dividend Growth	n/a
Payout Ratio	22.06%
Buyback Yield	n/a
Shareholder Yield	0.37%
Earnings Yield	5.28%
FCF Yield	1.62%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on February 28, 2022. It was a forward split with a ratio of 1.02.

Last Split Date	Feb 28, 2022
Split Type	Forward
Split Ratio	1.02

Scores

Advent Pharma has an Altman Z-Score of 3.43 and a Piotroski F-Score of 5.

Altman Z-Score	3.43
Piotroski F-Score	5